GOA Therapeutics Corporation, a biotechnology company developing first-in-class drug candidates, announced on October 13, 2026 that the U.S. Securities and Exchange Commission has qualified its Tier 2 Regulation A offering statement. The company plans to launch online investment access through its website on Thursday, October 15, 2026. The qualified offering covers up to 5 million shares of common stock at US$15.00 per share, representing an aggregate offering value of up to US$75 million.
Offering Structure and Distribution
The Regulation A offering enables GOA to raise up to US$75 million from eligible investors through the sale of common stock. Separate from the qualified offering, GOA also contemplates additional exempt offers and sales of its common stock, with the combined aggregate offering value potentially reaching approximately US$300 million. The company has engaged DealMaker Securities LLC, a registered broker-dealer and member of FINRA and SIPC, to provide broker-dealer services in connection with the Regulation A offering.
GOA26 and Clinical Rationale
GOA Therapeutics is initially developing GOA26 for intravenous administration in hospital emergency departments and trauma centers. The investigational candidate is designed to rapidly lower blood alcohol concentration and sequester acetaldehyde, a toxic byproduct of alcohol metabolism. In preclinical porcine studies involving severe alcohol intoxication, blood alcohol concentration was 61.3% lower in the GOA26-treated group than in the untreated control group at 20 minutes after administration.
Preclinical Evidence and Regulatory Status
These preclinical findings do not establish the safety or efficacy of GOA26 in humans, and the candidate has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. According to GOA, there is currently no FDA-approved medicine that directly and rapidly removes alcohol from the bloodstream in patients presenting with acute alcohol intoxication. The company believes the scale of the medical need warrants building resources to pursue the opportunity aggressively and responsibly.
Use of Proceeds and Leadership Commentary
GOA expects to use proceeds available to the company from its financing activities to advance GOA26 into and through clinical development. Planned uses also include research and development, manufacturing, medical affairs, regulatory activities, intellectual property, commercialization planning, working capital, and other general corporate purposes. Andrew Altschuler, Co-Founder and CEO of GOA Therapeutics, said, "No family should lose someone they love because they had too much to drink."
Development Goals and Investor Risks
Altschuler added that the company has been working for more than a decade to build the science behind GOA26. He said capital is the fuel that powers the mission to change how alcohol emergencies are treated and prevent families from losing loved ones to alcohol poisoning. The company aims to develop better treatment options and advance GOA26 through clinical development and, if approved, to patients.
Offering Circular and Regulatory Compliance
Investors considering the Regulation A offering should read the most recent offering circular filed with the SEC, including its risk factors and offering terms. No offer or sale will be made in any jurisdiction where it would be unlawful. SEC qualification does not constitute approval or endorsement of GOA, its securities, or the offering.
The announcement highlights GOA Therapeutics' effort to address a significant unmet need in emergency medicine through both scientific development and expanded investor access. The company has cautioned that GOA26 remains investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Investors face significant risk, including the possible loss of their entire investment, and there is currently no public trading market for GOA securities.